Table 2.
Biomarker characteristics
| Controls | Cases | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Mean (SD) | Median (Q1, Q3) | Mean (SD) | Median (Q1, Q3) | AUC (95% CI) | |||||
| All Participants: | |||||||||
| freePSA (ng/ml) | 0.5 | (0.4) | 0.3 | (0.2, 0.5) | 0.9 | (1.1) | 0.6 | (0.5, 1) | 0.76 (0.71, 0.8) |
| [−2]proPSA (pg/ml) | 8.9 | (5.7) | 7.2 | (5.3, 11) | 18.1 | (34.5) | 11.8 | (8.3, 18.3) | 0.72 (0.67, 0.76) |
| phi | 24.5 | (9.7) | 22.8 | (18.2, 29.7) | 42.9 | (45) | 32.9 | (23.8, 47) | 0.73 (0.68, 0.77) |
| %freePSA* | 31.9 | (11.6) | 30.4 | (24, 39) | 21.6 | (11.6) | 18.5 | (13.5, 27.2) | 0.76 (0.72, 0.8) |
| %[−2]proPSA* | 2.2 | (0.8) | 2.1 | (1.6, 2.6) | 2 | (0.9) | 1.8 | (1.4, 2.3) | 0.61 (0.56, 0.66) |
| DKK1 (ng/ml)* | 1.24 (0.66) | 1.15 (0.76, 1.61) | 1.2 | (0.73) | 1.08 (0.75, 1.43) | 0.53 (0.48, 0.58) | |||
| NEM (ng/ml) | 0.93 (3.15) | 0.13 (0.05, 0.44) | 1.14 (4.23) | 0.17 (0.06, 0.61) | 0.53 (0.48, 0.59) | ||||
| PSA 2–10 ng/ml: | |||||||||
| freePSA (ng/ml)* | 1 | (0.6) | 0.9 | (0.6, 1.3) | 0.8 | (0.5) | 0.7 | (0.5, 1.1) | 0.58 (0.49, 0.67) |
| [−2]proPSA (pg/ml)* | 15 | (7.3) | 14.4 | (9.2, 20.3) | 14.7 | (8.1) | 12.9 | (9, 18.7) | 0.53 (0.44, 0.62) |
| phi | 32.4 | (10) | 32.1 | (24.9, 37.7) | 39.7 | (21) | 35.5 | (27, 47) | 0.59 (0.51, 0.67) |
| %freePSA* | 23.9 | (8.1) | 24.1 | (18.7, 28.2) | 19.4 | (9) | 17.7 | (12.4, 24.5) | 0.67 (0.59, 0.75) |
| %[−2]proPSA | 1.7 | (0.6) | 1.5 | (1.3, 2) | 1.9 | (0.8) | 1.8 | (1.4, 2.2) | 0.57 (0.49, 0.65) |
*
Marker is under-expressed in cancer cases.